Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Prinses Maxima Centrum voor Kinderoncologie B.V.
Sponsor

Prinses Maxima Centrum voor Kinderoncologie B.V.

The Netherlands Heidelberglaan 25, 3584 CS Utrecht, The Netherlands

About the sponsor

Research activity includes acute myeloid leukemia, acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia, and relapsed or refractory T-cell and B-cell lymphoblastic lymphoma. The portfolio also covers infant leukemia, FLT3-ITD-positive AML, KMT2A-rearranged ALL, and molecularly defined subgroups of pediatric hematologic malignancies.

  • Acute myeloid leukemia and relapsed/refractory AML
  • Acute lymphoblastic leukemia and infant ALL
  • Relapsed/refractory lymphoblastic lymphoma
  • Molecularly targeted leukemia subtypes

Interest extends to CAR T-cell therapy, molecularly guided treatment, WT1-directed vaccination, and infection prophylaxis in children with leukemia.

About Specializations

Prinses Maxima Centrum voor Kinderoncologie B.V. runs clinical trials in conditions such as Acute myeloid leukaemia, Acute lymphocytic leukaemia, Neuroblastoma, Precursor B-lymphoblastic lymphoma recurrent, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

23 clinical trials

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

B-cell type acute leukaemia

Recruiting

Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Fludarabine Phosphate
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Brain stem glioma+3

Recruiting

Study of ONC206 for children and young adults with newly diagnosed or recurrent diffuse midline glioma and other recurrent brain tumors

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute lymphocytic leukaemia+1

Recruiting

Study of Ziftomenib with Chemotherapy for Children with Relapsed or Refractory Acute Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute myeloid leukaemia

Recruiting

Study on Teicoplanin for Preventing Infections in Children with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Neuroblastoma

Recruiting

Study Comparing [18F]meta-fluorobenzylguanidine PET-CT and Iodine (123I) Iobenguane Scans for Detecting Neuroblastoma in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:[18F]Meta-Fluorobenzylguanidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute lymphocytic leukaemia+4

Recruiting

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Anaplastic large cell lymphoma T- and null-cell types+1

Recruiting

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute myeloid leukaemia

Recruiting

Study of Cytarabine, Daunorubicin, and Clofarabine for Children with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Clofarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Neuroblastoma+1

Recruiting

Study on Dinutuximab Beta with Chemotherapy for Children and Teens with Newly Diagnosed High-Risk Neuroblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Dinutuximab Beta
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute lymphocytic leukaemia+4

Recruiting

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Trametinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Acute myeloid leukaemia

Recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.